Deliverables
Key deliverables and the expected delivery date.
Most of our deliverables are confidential. For more information about our research, please refer to the “Scientific publications” page.
Outputs
Deliverables - WP2
Collecting evidence
- D2.1: A systematic review of the literature on barriers and enablers to vaccination uptake among underserved groups in Europe.
The focus will be studies published primarily in English language in or after 2005. The search strategy will combine the following concepts: population age (children and young people), geography (the European region), population group (underserved communities) and type of barriers and enablers (health systems focused).
Expected Delivery: Fourth quarter of 2022
- D2.2: Five qualitative studies describing barriers and enablers to vaccination for each of the five selected underserved groups:
1) The migrant and refugee community in Greece (with a focus on MMR and HPV vaccines)
2) Turkish adolescent females in the Netherlands (focus on HPV)
3) Moroccan adolescent females in the Netherlands (focus on HPV)
4) The Ukrainian migrant community in Poland (focus on MMR and HPV)
5) The Roma community in Slovakia (focus on HPV)
Expected Delivery: Fourth quarter of 2022
- D2.3: Three qualitative studies describing barriers and enablers to vaccination for each of the three underserved communities with uncommonly high vaccine uptake:
1) The Somali Community in Finland
2) The Arab Israeli community in Israel
3) The Bangladeshi community in the United Kingdom
Expected Delivery: Fourth quarter of 2022
- D2.4: Literature review to identify interventions that improve vaccine uptake among underserved groups. A review will take into consideration how and why complex social interventions work in certain situations, rather than assume they either do or do not work at all. One of the components of the review will explore the situational factors that enable interventions to have a positive impact. This information will enable the development, implementation and evaluation of tailored interventions for the five target communities with low-vaccine uptake.
Expected Delivery: Fourth quarter of 2022
Most of our deliverables are confidential. For more information about our research, please refer to the “Scientific publications” page.
WP2 Leader: Bar Ilan University (BIU).
Deliverables - WP3
Development or adjustment of tailored interventions
- D3.1: A report with an assessment of the likelihood of successful transfer of vaccine uptake promoting interventions, naming barriers and facilitators for transfer; including indications and recommendations for adaptations of the interventions to better fit the target context and a successful implementation therein.
Expected Delivery: Fourth quarter of 2022
- D3.2: A selection of health system barriers to be addressed will be made for each of the five underserved communities.
Expected Delivery: Third quarter of 2022
- D3.3: A matrix per intervention will be developed, containing intervention objectives, including the barriers and facilitators to be influenced.
Expected Delivery: First quarter of 2023
- D3.4: A provisional list of potential methods and strategies for intervention implementation based on experts’ input, consultation of target communities and the literature review.
Expected Delivery: Third quarter of 2023
- D3.5: Development of coherent interventions
Expected Delivery: Third quarter of 2023
Most of our deliverables are confidential. For more information about our research, please refer to the “Scientific publications” page.
WP3 Leader: Academisch Ziekenhuis Groningen (UMCG), the Netherlands
WP3 Co-Leader (Tasks 3.1, 3.2): Maastricht University
Deliverables - WP4
Implementation and Evaluation of tailored interventions:
- D4.1: Preparation of the implementation plans including monitoring and evaluation frameworks (1 for each intervention)
Expected Delivery: Fourth quarter of 2023 - D4.2: Implementation reports including monitoring/evaluation results (quantitative, qualitative and cost effectiveness), one for each community where the intervention is implemented.
Expected Delivery: Fourth quarter of 2025 - D4.3: Overall report presenting key findings from individual implementations.
Expected Delivery: First quarter of 2026
Most of our deliverables are confidential. For more information about our research, please refer to the “Scientific publications” page.
WP3 Leader: Astiki Mikerdoskopiki Etaireia Prolipsis (Prolepsis), Greece
WP4 Co-Leader (Task 4.3.2):Academisch Ziekenhuis Groningen (UMCG), the Netherlands
Deliverables - WP5
Guideline development
- D5.1: The creation of guidelines that will be applicable to all EU countries and will enable them to remove health systems barriers to immunisation among underserved communities.
Expected Delivery: First quarter of 2026
The guidelines will be accompanied by:
- D5.2: Action framework applicable to all three levels targeted by the guidelines (national, subnational and facility) to ensure that they are implementable and relevant to the operational level in each country
Expected Delivery: First quarter of 2026 - D5.3: Interactive tool - an online version of the guidelines and action framework
Expected Delivery: First quarter of 2026
Most of our deliverables are confidential. For more information about our research, please refer to the “Scientific publications” page.
WP5 Leader:UK Health Security Agency (UKHSA)
Deliverables - WP6
Strengthening Education and Knowledge on Immunisation (SEKI)
- D6.1: Establishment of an online system with up-to-date educational content for healthcare workers and medical students, which presents the possibility to register for educational activities and to collect training points once the platform has passed the testing phase.
Expected Delivery: Second quarter of 2023
- D6.2: Report based on lessons learned in RIVER-EU and exclusive Strengthening Education and Knowledge on Immunisation (SEKI) training materials dedicated to cultural competency working on migrant and minority health, as well as online platform sustainability.
Expected Delivery: Second quarter of 2026
Most of our deliverables are confidential. For more information about our research, please refer to the “Scientific publications” page.
WP6 Leader: Vaccine Safety Initiative
Deliverables - WP7
Dissemination and exploitation
- D7.1: Dissemination and Communication Plan and visual identity, and website launch.
Expected Delivery: Third quarter of 2021 - D7.2: A report on the engagement of target groups will be produced in M24, to assess the need for changes in strategy.
Expected Delivery: Second quarter of 2023 - D7.3: Exploitation plan.
Expected Delivery: Second quarter of 2025
Most of our deliverables are confidential. For more information about our research, please refer to the “Scientific publications” page.
WP7 Leader: EuroHealthNet
WP7 Co-Lead: Connaxis
Project timeline
Collecting evidence
- D2.1 :A systematic review of the literature on barriers and enablers to vaccination uptake among underserved groups in Europe.
The focus will be studies published primarily in English language in or after 2005. The search strategy will combine the following concepts: population age (children and young people), geography (the European region), population group (underserved communities) and type of barriers and enablers (health systems focused).
Expected Delivery: Fourth quarter of 2022 - D2.2: Five qualitative studies describing barriers and enablers to vaccination for each of the five selected underserved groups:
1) The migrant and refugee community in Greece (with a focus on MMR and HPV vaccines)
2) Turkish adolescent females in the Netherlands (focus on HPV)
3) Moroccan adolescent females in the Netherlands (focus on HPV)
4) The Ukrainian migrant community in Poland (focus on MMR and HPV)
5) The Roma community in Slovakia (focus on HPV)
Expected Delivery: Fourth quarter of 2022
- D2.3: Three qualitative studies describing barriers and enablers to vaccination for each of the three underserved communities with uncommonly high vaccine uptake:
1) The Somali Community in Finland
2) The Arab Israeli community in Israel
3) The Bangladeshi community in the United Kingdom
Expected Delivery: Fourth quarter of 2022
- D2.4 Literature review to identify interventions that improve vaccine uptake among underserved groups. A review will take into consideration how and why complex social interventions work in certain situations, rather than assume they either do or do not work at all. One of the components of the review will explore the situational factors that enable interventions to have a positive impact. This information will enable the development, implementation and evaluation of tailored interventions for the five target communities with low-vaccine uptake.
Expected Delivery: Fourth quarter of 2022
Some deliverables are initially confidential, but an executive summary will be made available immediately. The deliverable will become available on the website after the use of data for scientific publication(s).
WP2 Leader: Bar Ilan University (BIU).
Development or adjustment of tailored interventions
- D3.1: A report with an assessment of the likelihood of successful transfer of vaccine uptake promoting interventions, naming barriers and facilitators for transfer; including indications and recommendations for adaptations of the interventions to better fit the target context and a successful implementation therein.
Expected Delivery: Fourth quarter of 2022 - D3.2: A selection of health system barriers to be addressed will be made for each of the five underserved communities.
Expected Delivery: Third quarter of 2022 - D3.3: A matrix per intervention will be developed, containing intervention objectives, including the barriers and facilitators to be influenced.
Expected Delivery: First quarter of 2023 - D3.4: A provisional list of potential methods and strategies for intervention implementation based on experts’ input, consultation of target communities and the literature review.
Expected Delivery: Third quarter of 2023 - D 3.5: Development of coherent interventions
Expected Delivery: Third quarter of 2023
Some deliverables are initially confidential, but an executive summary will be made available immediately. The deliverable will become available on the website after the use of data for scientific publication(s).
WP3 Leader: Academisch Ziekenhuis Groningen (UMCG), the Netherlands
WP3 Co-Leader (Tasks 3.1, 3.2): Maastricht University
Implementation and Evaluation of tailored interventions:
- D4.1: Preparation of the implementation plans including monitoring and evaluation frameworks (1 for each intervention)
Expected Delivery: Fourth quarter of 2023 - D4.2: Implementation reports including monitoring/evaluation results (quantitative, qualitative and cost effectiveness), one for each community where the intervention is implemented.
Expected Delivery: Fourth quarter of 2025 - D4.3: Overall report presenting key findings from individual implementations.
Expected Delivery: First quarter of 2026
Some deliverables are initially confidential, but an executive summary will be made available immediately. The deliverable will become available on the website after the use of data for scientific publication(s).
WP3 Leader: Astiki Mikerdoskopiki Etaireia Prolipsis (Prolepsis), Greece
WP4 Co-Leader (Task 4.3.2):Academisch Ziekenhuis Groningen (UMCG), the Netherlands
Guideline development
- D 5.1: The creation of guidelines that will be applicable to all EU countries and will enable them to remove health systems barriers to immunisation among underserved communities.
The guidelines will be accompanied by:
- D 5.2: Action framework applicable to all three levels targeted by the guidelines (national, subnational and facility) to ensure that they are implementable and relevant to the operational level in each country
- D 5.3: Interactive tool – an online version of the guidelines and action framework
Expected Delivery: First quarter of 2026
Some deliverables are initially confidential, but an executive summary will be made available immediately. The deliverable will become available on the website after the use of data for scientific publication(s).
WP5 Leader:UK Health Security Agency (UKHSA)
Strengthening Education and Knowledge on Immunisation (SEKI)
- D6.1 Establishment of an online system with up-to-date educational content for healthcare workers and medical students, which presents the possibility to register for educational activities and to collect training points once the platform has passed the testing phase.
Second quarter of 2023
- D6.2 Report based on lessons learned in RIVER-EU and exclusive Strengthening Education and Knowledge on Immunisation (SEKI) training materials dedicated to cultural competency working on migrant and minority health, as well as online platform sustainability.
Expected Delivery: Second quarter of 2026
Some deliverables are initially confidential, but an executive summary will be made available immediately. The deliverable will become available on the website after the use of data for scientific publication(s).
WP6 Leader: Vaccine Safety Initiative
Dissemination and exploitation
- D7.1 Dissemination and Communication Plan and visual identity, and website launch.
Expected Delivery: Third quarter of 2021 - D7.2 A report on the engagement of target groups will be produced in M24, to assess the need for changes in strategy.
Expected Delivery: Second quarter of 2023 - D7.3 Exploitation plan.
Expected Delivery: Second quarter of 2025
Some deliverables are initially confidential, but an executive summary will be made available immediately. The deliverable will become available on the website after the use of data for scientific publication(s).
WP7 Leader: EuroHealthNet
WP7 Co-Lead: Connaxis